Icahn School of Medicine spinout Sema4 has completed a reverse merger with CM Life Sciences to begin trading on the Nasdaq Global Select Market.

Sema4, a US-based health information company based on research at health system Mount Sinai Health System’s private college Icahn School of Medicine, has completed a reverse merger with special purpose acquisition vehicle (Spac) CM Life Sciences.
The combined business is now trading its common stock and warrants on the Nasdaq Global Select Market under the ticker symbols SMFR and SMFRW, respectively. Shares are trading at $11.19 as of the time of writing.
The merger provided Sema4 with…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in